AbbVie’s inclusion in the third cycle of the Medicare Drug Price Negotiation Program was announced on January 27, 2026, marking the first time that physician‑administered Part B drugs are subject to federal price negotiations. The program, established under the Inflation Reduction Act, allows Medicare to negotiate prices for high‑cost specialty drugs that lack generic or biosimilar competition.
The drugs selected for negotiation include AbbVie’s Botox and Cosentyx, both of which are high‑margin products that generate a significant portion of the company’s Medicare‑B revenue. Negotiations are expected to take place throughout 2026, with any resulting price changes taking effect on January 1, 2028. The inclusion signals a broader expansion of the program’s reach and introduces new pricing pressure on AbbVie’s most profitable outpatient therapies.
AbbVie reported $15.78 billion in revenue for the quarter ended October 31, 2025, with earnings per share of $3.00. Management guided for 2025 EPS of $3.32–$3.36, a slight uptick from the prior year’s $3.00, reflecting confidence in continued growth of its immunology and neuroscience portfolio. Medicare‑B revenue accounted for roughly 12% of total sales, so any negotiated price reductions could translate into a measurable drag on the company’s top line and margin profile. The company has not yet quantified the financial impact, but analysts anticipate that the new program could compress reimbursement rates for Botox and Cosentyx by 5–10% once the negotiations conclude.
The regulatory risk is significant because Part B drugs are typically administered in outpatient settings and carry higher per‑unit costs than many Part D products. A price cut would reduce AbbVie’s gross margin on these products, potentially offsetting gains from its newer growth drivers such as Skyrizi and Rinvoq. Management has emphasized that it will continue to invest in its pipeline and maintain pricing power through product differentiation, but the program introduces a new headwind that could constrain future cash flows and alter the company’s pricing strategy.
Market reaction to the announcement was muted; AbbVie’s shares rose 1.43% on the day of the announcement, reflecting a balance between the company’s strong earnings guidance and the perceived regulatory risk. The broader market view is that while the program may reduce Medicare‑B margins, it does not immediately threaten AbbVie’s overall profitability, which remains supported by its diversified portfolio and robust pipeline.
In summary, AbbVie’s addition to the Medicare Part B negotiation program represents a material shift in its reimbursement environment. The company will need to monitor the negotiation outcomes closely, as any price reductions could materially affect its Medicare‑B revenue and overall profitability, while its strategic focus on high‑margin immunology and neuroscience products will remain critical to sustaining growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.